… On the basis of phase II results and the therapeutic advantage demonstrated … with erlotinib
with platinum-based and taxane chemotherapy, a phase III trial was conducted using erlotinib …

… - or third-line treatment for refractory ovarian cancer (doxorubicin and topotecan).28, 29 A
phase II clinical trial is in progress examining erlotinib in combination with carboplatin, and two …

… Erlotinib (150 mg/day po until disease progression) was shown to have significant
antitumor activity in a phase II trial involving 56 patients suffering from stage IIIB/IV or recurrent …

… , respectively, conducted a Phase II trial of erlotinib and bevacizumab in advanced … The
combination was safe and well-tolerated, and enough activity was seen to justify a Phase III …

… Recent data from a phase 3 trial of erlotinib in combination with gemcitabine in patients with
advanced pancreatic cancer showed a 23.5% improvement in survival with the addition of …

… Methods: A multi-institutional phase II clinical trial of the … Pharmacokinetic measurements
are being obtained in this study. … Conclusions: These preliminary data suggest that erlotinib is …

… toxicities, and ease of administration, erlotinib is a possible candidate for … a phase II study
of erlotinib in 34 heavily pretreated patients with relapsed cancer of the ovary at the phase I …

… TRIBUTE was a prospective, placebo-controlled study randomizing patients (pts) with
previously untreated advanced (Stage IIIB / IV) NSCLC to receive erlotinib at 150 mg/d or placebo (…

… The results of 3 phase II studies with erlotinib in non–small-cell lung cancer (NSCLC) are …
Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol …

… a phase II trial with erlotinib in patients with non-small cell lung cancer, 17 findings from
recent phase II studies … NSCLC treated with Tarceva (erlotinib HCl; OSI-774). Final report of a …